IGBT
Lifer
Text
First in Class of Cannabinoid-1 Receptor Blockers
"The study showed that Acomplia is effective -- and as effective, if not a little more, than the two other drugs already approved for weight loss: sibutramine and orlistat," the study's lead author F. Xavier Pi-Sunyer, of St. Luke's-Roosevelt Hospital Center, told United Press International.
"It's an advance," Pi-Sunyer said, adding that he had no other ties, financial or otherwise, to the company.
"It's unusual in that it's a two-year trial and it shows continued effect over two years," he said. "In addition, the drug works by a different mechanism of action, so it has the potential to be important."
If Acomplia is approved by the FDA, it would be the first in class of drugs known as selective cannabinoid-1 receptor blockers.
Sanofi-Aventis said in a statement that the results are consistent with three other phase 3 trials involving Acomplia.
First in Class of Cannabinoid-1 Receptor Blockers
"The study showed that Acomplia is effective -- and as effective, if not a little more, than the two other drugs already approved for weight loss: sibutramine and orlistat," the study's lead author F. Xavier Pi-Sunyer, of St. Luke's-Roosevelt Hospital Center, told United Press International.
"It's an advance," Pi-Sunyer said, adding that he had no other ties, financial or otherwise, to the company.
"It's unusual in that it's a two-year trial and it shows continued effect over two years," he said. "In addition, the drug works by a different mechanism of action, so it has the potential to be important."
If Acomplia is approved by the FDA, it would be the first in class of drugs known as selective cannabinoid-1 receptor blockers.
Sanofi-Aventis said in a statement that the results are consistent with three other phase 3 trials involving Acomplia.
